Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Brookfield Business Partners LP (NYSE:BBU) Unit stock reached a 52-week high of $27.08, with a market capitalization of $5.7 billion and impressive EBITDA of $7.2 billion, underscoring a significant upward trend for the company. InvestingPro analysis suggests the stock is slightly overvalued at current levels. Over the past year, the stock has experienced a remarkable 43.03% increase, reflecting strong investor confidence and robust business performance. This milestone highlights the company’s resilience and growth potential in a competitive market, supported by management’s aggressive share buybacks and a 10-year track record of consistent dividend payments. Brookfield Business Partners continues to capture investor interest, as evidenced by this recent peak, positioning itself as a noteworthy player in the industry. Discover 8 additional exclusive insights about BBU with InvestingPro’s comprehensive analysis.
In other recent news, Brookfield Business Partners reported mixed results for the first quarter, with earnings surpassing expectations but revenue experiencing a significant decline. The company announced adjusted earnings per share of $0.38, exceeding analyst projections and up from $0.23 in the same quarter last year. However, revenue fell sharply to $6.75 billion from $12.02 billion year-over-year. Despite the revenue drop, Brookfield Business Partners saw an increase in Adjusted EBITDA to $591 million, reflecting improved operational efficiency. The Industrials segment performed well, with Adjusted EBITDA rising to $304 million, aided by tax benefits at the advanced energy storage operation. In contrast, the Infrastructure Services segment saw a decline in Adjusted EBITDA. Additionally, Brookfield Business Partners plans to acquire Antylia Scientific for approximately $1.3 billion, investing about $160 million for a 25% stake. In related developments, RBC Capital upgraded Brookfield Business Partners to an outperform rating, citing its strong investment performance and attractive valuation. The firm raised its price target to $33.00, highlighting the company’s effective capital deployment and ongoing share buybacks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.